Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.67 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11398234 | 0.86 | P4HTM (0.78) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL23745955 | 0.81 | HDAC1 (0.72) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL11389738 | 0.81 | CA1 (0.62) | HDAC1P4HTMKDM4EASPHRIOX2 | |
| SCHEMBL14875866 | 0.78 | HDAC6 (0.54) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL28551286 | 0.78 | RAB9A (0.57) | P4HTMKDM4E | |
| SCHEMBL20132433 | 0.76 | HDAC1 (0.71) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL11392796 | 0.75 | P4HTM (0.74) | HDAC1HDAC3P4HTMHDAC2NCOR1 | |
| SCHEMBL20161169 | 0.75 | P4HTM (0.51) | HDAC1HDAC4P4HTMKDM4EASPH | |
| SCHEMBL20132368 | 0.75 | HDAC6 (0.45) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL20132367 | 0.75 | ADORA2A (0.48) | HDAC1HDAC6HDAC3HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538084-B1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10927072-B2 | Phenyl and pyridinyl hydroxamic acids | ACETYLON PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10370324-B2 | Phenyl and pyridinyl hydroxamic acids | ACETYLON PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370324-B2 | Phenyl and pyridinyl hydroxamic acids | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 4/4885 |
| US-10927072-B2 | Phenyl and pyridinyl hydroxamic acids | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 4/4885 |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.